Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant
© 2020 The Author(s)..
Rapid COVID-19 diagnosis in the hospital is essential, although this is complicated by 30%-50% of nose/throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing (NAAT). Furthermore, the D614G spike mutant dominates the pandemic and it is unclear how serological tests designed to detect anti-spike antibodies perform against this variant. We assess the diagnostic accuracy of combined rapid antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease due to either wild-type or the D614G spike mutant SARS-CoV-2. The overall detection rate for COVID-19 is 79.2% (95% CI 57.8-92.9) by rapid NAAT alone. The combined point of care antibody test and rapid NAAT is not affected by D614G and results in very high sensitivity for COVID-19 diagnosis with very high specificity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1 |
|---|---|
| Enthalten in: |
Cell reports. Medicine - 1(2020), 6 vom: 22. Sept., Seite 100099 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mlcochova, Petra [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.02.2022 Date Revised 11.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.xcrm.2020.100099 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314776435 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314776435 | ||
| 003 | DE-627 | ||
| 005 | 20240211231834.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.xcrm.2020.100099 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1288.xml |
| 035 | |a (DE-627)NLM314776435 | ||
| 035 | |a (NLM)32905045 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mlcochova, Petra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.02.2022 | ||
| 500 | |a Date Revised 11.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Author(s). | ||
| 520 | |a Rapid COVID-19 diagnosis in the hospital is essential, although this is complicated by 30%-50% of nose/throat swabs being negative by SARS-CoV-2 nucleic acid amplification testing (NAAT). Furthermore, the D614G spike mutant dominates the pandemic and it is unclear how serological tests designed to detect anti-spike antibodies perform against this variant. We assess the diagnostic accuracy of combined rapid antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease due to either wild-type or the D614G spike mutant SARS-CoV-2. The overall detection rate for COVID-19 is 79.2% (95% CI 57.8-92.9) by rapid NAAT alone. The combined point of care antibody test and rapid NAAT is not affected by D614G and results in very high sensitivity for COVID-19 diagnosis with very high specificity | ||
| 650 | 4 | |a Evaluation Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a D614G | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a point of care testing | |
| 650 | 4 | |a rapid diagnoses | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Collier, Dami |e verfasserin |4 aut | |
| 700 | 1 | |a Ritchie, Allyson |e verfasserin |4 aut | |
| 700 | 1 | |a Assennato, Sonny M |e verfasserin |4 aut | |
| 700 | 1 | |a Hosmillo, Myra |e verfasserin |4 aut | |
| 700 | 1 | |a Goel, Neha |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Bo |e verfasserin |4 aut | |
| 700 | 1 | |a Chatterjee, Krishna |e verfasserin |4 aut | |
| 700 | 1 | |a Mendoza, Vivien |e verfasserin |4 aut | |
| 700 | 1 | |a Temperton, Nigel |e verfasserin |4 aut | |
| 700 | 1 | |a Kiss, Leo |e verfasserin |4 aut | |
| 700 | 1 | |a James, Leo C |e verfasserin |4 aut | |
| 700 | 1 | |a Ciazynska, Katarzyna A |e verfasserin |4 aut | |
| 700 | 1 | |a Xiong, Xiaoli |e verfasserin |4 aut | |
| 700 | 1 | |a Briggs, John A G |e verfasserin |4 aut | |
| 700 | 1 | |a Nathan, James A |e verfasserin |4 aut | |
| 700 | 1 | |a Mescia, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Bergamaschi, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Hongyi |e verfasserin |4 aut | |
| 700 | 1 | |a Barmpounakis, Petros |e verfasserin |4 aut | |
| 700 | 1 | |a Demeris, Nikos |e verfasserin |4 aut | |
| 700 | 1 | |a Skells, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Lyons, Paul A |e verfasserin |4 aut | |
| 700 | 1 | |a Bradley, John |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Allain, Jean Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Kenneth G C |e verfasserin |4 aut | |
| 700 | 1 | |a Bousfield, Rachel |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Sparkes, Dominic |e verfasserin |4 aut | |
| 700 | 1 | |a Amoroso, Glenn |e verfasserin |4 aut | |
| 700 | 1 | |a Gkrania-Klotsas, Effrosyni |e verfasserin |4 aut | |
| 700 | 1 | |a Hardwick, Susie |e verfasserin |4 aut | |
| 700 | 1 | |a Boyle, Adrian |e verfasserin |4 aut | |
| 700 | 1 | |a Goodfellow, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Ravindra K |e verfasserin |4 aut | |
| 700 | 0 | |a Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration |e verfasserin |4 aut | |
| 700 | 1 | |a Baker, Stephen |e investigator |4 oth | |
| 700 | 1 | |a Bradley, John |e investigator |4 oth | |
| 700 | 1 | |a Dougan, Gordon |e investigator |4 oth | |
| 700 | 1 | |a Goodfellow, Ian |e investigator |4 oth | |
| 700 | 1 | |a Gupta, Ravi |e investigator |4 oth | |
| 700 | 1 | |a Lehner, Paul J |e investigator |4 oth | |
| 700 | 1 | |a Lyons, Paul |e investigator |4 oth | |
| 700 | 1 | |a Matheson, Nicholas J |e investigator |4 oth | |
| 700 | 1 | |a Smith, Kenneth Gc |e investigator |4 oth | |
| 700 | 1 | |a Toshner, Mark |e investigator |4 oth | |
| 700 | 1 | |a Weekes, Michael P |e investigator |4 oth | |
| 700 | 1 | |a Brown, Nick |e investigator |4 oth | |
| 700 | 1 | |a Curran, Martin |e investigator |4 oth | |
| 700 | 1 | |a Palmar, Surendra |e investigator |4 oth | |
| 700 | 1 | |a Zhang, Hongyi |e investigator |4 oth | |
| 700 | 1 | |a Enoch, David |e investigator |4 oth | |
| 700 | 1 | |a Chapman, Daniel |e investigator |4 oth | |
| 700 | 1 | |a Shaw, Ashley |e investigator |4 oth | |
| 700 | 1 | |a Jose, Sherly |e investigator |4 oth | |
| 700 | 1 | |a Bermperi, Areti |e investigator |4 oth | |
| 700 | 1 | |a Zerrudo, Julie Ann |e investigator |4 oth | |
| 700 | 1 | |a Kourampa, Evgenia |e investigator |4 oth | |
| 700 | 1 | |a Watson, Laura |e investigator |4 oth | |
| 700 | 1 | |a Worsley, Jieniean |e investigator |4 oth | |
| 700 | 1 | |a Saunders, Caroline |e investigator |4 oth | |
| 700 | 1 | |a de Jesus, Ranalie |e investigator |4 oth | |
| 700 | 1 | |a Domingo, Jason |e investigator |4 oth | |
| 700 | 1 | |a Pasquale, Ciro |e investigator |4 oth | |
| 700 | 1 | |a Vergese, Bensi |e investigator |4 oth | |
| 700 | 1 | |a Vargas, Phoebe |e investigator |4 oth | |
| 700 | 1 | |a Fabiculana, Marivic |e investigator |4 oth | |
| 700 | 1 | |a Perales, Marlyn |e investigator |4 oth | |
| 700 | 1 | |a Mynott, Lee |e investigator |4 oth | |
| 700 | 1 | |a Blake, Elizabeth |e investigator |4 oth | |
| 700 | 1 | |a Bates, Amy |e investigator |4 oth | |
| 700 | 1 | |a Vallier, Anne-Laure |e investigator |4 oth | |
| 700 | 1 | |a Williams, Alexandra |e investigator |4 oth | |
| 700 | 1 | |a Phillips, David |e investigator |4 oth | |
| 700 | 1 | |a Chiu, Edmund |e investigator |4 oth | |
| 700 | 1 | |a Overhill, Alex |e investigator |4 oth | |
| 700 | 1 | |a Ramenatte, Nicola |e investigator |4 oth | |
| 700 | 1 | |a Sipple, Jamal |e investigator |4 oth | |
| 700 | 1 | |a Frost, Steven |e investigator |4 oth | |
| 700 | 1 | |a Knock, Helena |e investigator |4 oth | |
| 700 | 1 | |a Hardy, Richard |e investigator |4 oth | |
| 700 | 1 | |a Foster, Emily |e investigator |4 oth | |
| 700 | 1 | |a Davidson, Fiona |e investigator |4 oth | |
| 700 | 1 | |a Rundell, Viona |e investigator |4 oth | |
| 700 | 1 | |a Bundi, Purity |e investigator |4 oth | |
| 700 | 1 | |a Abeseabe, Richmond |e investigator |4 oth | |
| 700 | 1 | |a Clark, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Vicente, Isabel |e investigator |4 oth | |
| 700 | 1 | |a Watson, Laura |e investigator |4 oth | |
| 700 | 1 | |a Worsley, Jieniean |e investigator |4 oth | |
| 700 | 1 | |a Elmer, Anne |e investigator |4 oth | |
| 700 | 1 | |a Ribeiro, Carla |e investigator |4 oth | |
| 700 | 1 | |a Kourampa, Jenny |e investigator |4 oth | |
| 700 | 1 | |a Jose, Sherly |e investigator |4 oth | |
| 700 | 1 | |a Kennet, Jane |e investigator |4 oth | |
| 700 | 1 | |a Rowlands, Jane |e investigator |4 oth | |
| 700 | 1 | |a Meadows, Anne |e investigator |4 oth | |
| 700 | 1 | |a O'Brien, Criona |e investigator |4 oth | |
| 700 | 1 | |a Rastall, Rebecca |e investigator |4 oth | |
| 700 | 1 | |a Crucusio, Cherry |e investigator |4 oth | |
| 700 | 1 | |a Hewitt, Sarah |e investigator |4 oth | |
| 700 | 1 | |a Price, Jane |e investigator |4 oth | |
| 700 | 1 | |a Calder, Jo |e investigator |4 oth | |
| 700 | 1 | |a Canna, Laura |e investigator |4 oth | |
| 700 | 1 | |a Bucke, Ashlea |e investigator |4 oth | |
| 700 | 1 | |a Tordesillas, Hugo |e investigator |4 oth | |
| 700 | 1 | |a Harris, Julie |e investigator |4 oth | |
| 700 | 1 | |a Ruffolo, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Domingo, Jason |e investigator |4 oth | |
| 700 | 1 | |a Graves, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Butcher, Helen |e investigator |4 oth | |
| 700 | 1 | |a Caputo, Daniela |e investigator |4 oth | |
| 700 | 1 | |a Le Gresley, Emma |e investigator |4 oth | |
| 700 | 1 | |a Dunmore, Benjamin J |e investigator |4 oth | |
| 700 | 1 | |a Martin, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Legchenko, Ekaterina |e investigator |4 oth | |
| 700 | 1 | |a Treacy, Carmen |e investigator |4 oth | |
| 700 | 1 | |a Huang, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Wood, Jennifer |e investigator |4 oth | |
| 700 | 1 | |a Sutcliffe, Rachel |e investigator |4 oth | |
| 700 | 1 | |a Hodgson, Josh |e investigator |4 oth | |
| 700 | 1 | |a Shih, Joy |e investigator |4 oth | |
| 700 | 1 | |a Graf, Stefan |e investigator |4 oth | |
| 700 | 1 | |a Tong, Zhen |e investigator |4 oth | |
| 700 | 1 | |a Mescia, Federica |e investigator |4 oth | |
| 700 | 1 | |a Tilly, Tobias |e investigator |4 oth | |
| 700 | 1 | |a O'Donnell, Ciara |e investigator |4 oth | |
| 700 | 1 | |a Hunter, Kelvin |e investigator |4 oth | |
| 700 | 1 | |a Pointon, Linda |e investigator |4 oth | |
| 700 | 1 | |a Pond, Nicole |e investigator |4 oth | |
| 700 | 1 | |a Wylot, Marta |e investigator |4 oth | |
| 700 | 1 | |a Jones, Emma |e investigator |4 oth | |
| 700 | 1 | |a Fawke, Stuart |e investigator |4 oth | |
| 700 | 1 | |a Bullman, Ben |e investigator |4 oth | |
| 700 | 1 | |a Turner, Lori |e investigator |4 oth | |
| 700 | 1 | |a Jarvis, Isobel |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d 2020 |g 1(2020), 6 vom: 22. Sept., Seite 100099 |w (DE-627)NLM310587662 |x 2666-3791 |7 nnns |
| 773 | 1 | 8 | |g volume:1 |g year:2020 |g number:6 |g day:22 |g month:09 |g pages:100099 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xcrm.2020.100099 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1 |j 2020 |e 6 |b 22 |c 09 |h 100099 | ||